Oncology

Main Research: Oncology

Term: 01.01.2018 – 30.06.2021

AML is the most common acute leukemia in adults. Emerging evidence suggests that immune alterations favor leukemogenesis and relapse. Myeloid derived suppressor cells (MDSCs) are mediators of tumor immune escape. Here, we aim to decipher the interconnection between metabolic reprogramming and MDSC abundance in AML and to unravel the role of AML-derived exosomes in this context. A better understanding is key for improving immune-based therapeutic approaches in AML

Principal Investigator
Dr. Regina Jitschin
phone: +49 9131 85-43113
e-mail: regina.jitschin@uk-erlangen.de

J67: Regina Jitschin, Department of Medicine 5 Metabolic reprogramming of AML MDSCs